Bloomberg reported that months after Valeant Pharmaceuticals pledged to make discounts available to US hospitals for its cardiovascular drugs Isuprel and Nitropress, some medical centers say they have yet to see any savings.
Valeant told the US Congress in April that it would work to cut prices for Isuprel and Nitropress amid a public outcry triggered when the company raised the drugs' prices by 525 percent and 212 percent, respectively, after acquiring them last year.
Bloomberg contacted 23 hospital systems and purchasing groups selected from lists of the US's largest or top-rated hospitals, and found that 11 said they were not yet getting lower prices on one or both drugs. Meanwhile, one large hospital system and one purchasing group said they were getting discounts, while 10 others either declined to comment or did not respond.
Valeant issued a statement recently saying that all group purchasing organizations (GPOs) and hospitals were eligible for discounts of 10 percent to 40 percent that were announced in May.
CEO Joseph Papa remarked "everybody has access to that 10 percent, either through the GPO or negotiating directly with us," adding that "the more they use, the more they'd be eligible for additional volume rebates."
However, Bloomberg indicated that some of the hospital executives it interviewed have expressed confusion or frustration over trying to access the program.
To read more NewsPoints articles, click here.